Core Viewpoint - The Hong Kong capital market is experiencing a significant recovery in 2025, with IPO financing reaching 132.9 billion HKD, a 50% increase compared to the entire year of 2024 [3] Group 1: Market Performance - As of the first eight months of 2025, the IPO financing scale in Hong Kong reached 132.9 billion HKD, marking a four-year high [3] - The secondary market for Hong Kong stocks has shown even stronger performance, with fundraising reaching 190.5 billion HKD, which is 3.8 times higher than the total for 2024 [3] - The average fundraising scale per project in the secondary market is 1.1 billion HKD, contributing significantly to the market's activity [3] Group 2: Industry Financing - The top three industries in terms of financing scale are Information Technology, Consumer Discretionary, and Healthcare, with the Healthcare sector raising 37 billion HKD [4] - Notably, four out of the top ten refinancing projects in 2025 are related to innovative drugs, collectively raising 19.9 billion HKD [4] Group 3: Company-Specific Financing Activities - WuXi AppTec led the medical sector with a 77 billion HKD fundraising through a lightning placement, marking the largest medical project financing of the year [6] - The company reported a 20.6% year-on-year increase in revenue for the first half of 2025, reaching 20.8 billion HKD, and a 95% increase in net profit [6] - Innovent Biologics raised 43.1 billion HKD with a 4.9% discount, benefiting from a 46% increase in revenue and a 302% surge in net profit [9] - Kangfang Biologics raised 39.7 billion HKD at a 4.75% discount, despite being the only company in the healthcare sector to report a decline in net profit for two consecutive reporting periods [11] - Hansoh Pharmaceutical raised 39.2 billion HKD with a 6.5% discount, utilizing a firm underwriting model to ensure full subscription of shares [12]

Market Overview - On September 10, the Hang Seng Index rose by 1.01%, closing at 26,200.26 points, with a total net inflow of southbound funds through the Stock Connect amounting to HKD 75.66 billion [1][3] - The total trading volume for the Stock Connect on the same day was HKD 1,393.07 billion, with a net buy of HKD 75.66 billion [1] Stock Performance - In the Shanghai Stock Connect, the total trading volume was HKD 867.41 billion, with a net buy of HKD 25.36 billion; in the Shenzhen Stock Connect, the trading volume was HKD 525.66 billion, with a net buy of HKD 50.30 billion [1] - The most actively traded stock in the Shanghai Stock Connect was Alibaba-W, with a trading volume of HKD 1,090.16 million and a net buy of HKD 242.57 million, closing up by 0.63% [2] - In the Shenzhen Stock Connect, Alibaba-W also led with a trading volume of HKD 589.33 million and a net buy of HKD 208.56 million, closing up by 0.63% [2] Notable Stocks - The stock with the highest net sell was Pop Mart, with a net sell of HKD 129.84 million, closing down by 4.51% [2] - Other notable stocks included Semiconductor Manufacturing International Corporation (SMIC) with a net buy of HKD 11.94 million and a closing increase of 3.61%, and Tencent Holdings with a net buy of HKD 2.32 million, closing up by 1.04% [2]

Group 1 - Significant net purchases were made in Alibaba (HKD 4.511 billion), Bilibili (HKD 0.362 billion), and other companies, while major net sales were recorded for Pop Mart (HKD 1.711 billion) and others [1] - Southbound funds have continuously net purchased Alibaba for 14 days, totaling HKD 33.41389 billion, while Pop Mart and Xiaomi have seen net sales over the last three days [3] Group 2 - Alibaba launched a new product called "Gaode Street Ranking," which utilizes AI algorithms to quantify user behavior and create a credit system for offline services, enhancing visibility for lesser-known businesses [4] - Goldman Sachs reported that Bilibili's upcoming game "Three Kingdoms: Hundred Generals Card" is expected to achieve daily active users of one million, with a launch planned for the 2026 Spring Festival [4] Group 3 - The AI cloud market in China is projected to reach CNY 22.3 billion in the first half of 2025, with a significant growth forecast driven by generative AI [5] - Bank of America upgraded Kingsoft Cloud's rating to "Buy" with a target price of USD 20.4, while JPMorgan maintained a "Buy" rating and raised the target price to USD 19 [5] Group 4 - Xiaomi's marketing manager was dismissed for serious violations, including leaking confidential information, indicating potential internal governance issues [6]

Core Insights - On September 10, 2025, Alibaba-W (09988), Pop Mart (09992), and SMIC (00981) were the top three companies by trading volume in the Hong Kong Stock Connect (southbound), with trading amounts of 10.902 billion, 3.420 billion, and 3.019 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect (southbound), Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) led the trading volume, with amounts of 5.893 billion, 2.042 billion, and 1.720 billion respectively [1] Southbound Trading Activity - The top active companies in the Hong Kong Stock Connect (southbound) included: - Alibaba-W (09988) with a trading amount of 10.902 billion and a net buying amount of +2.426 billion - Pop Mart (09992) with a trading amount of 3.420 billion and a net selling amount of -1.298 billion - SMIC (00981) with a trading amount of 3.019 billion and a net buying amount of +0.119 billion [2] - The top active companies in the Shenzhen-Hong Kong Stock Connect (southbound) included: - Alibaba-W (09988) with a trading amount of 5.893 billion and a net buying amount of +2.086 billion - Tencent Holdings (00700) with a trading amount of 2.042 billion and a net selling amount of -0.094 billion - Xiaomi Group-W (01810) with a trading amount of 1.720 billion and a net selling amount of -0.0115 billion [2]

Core Viewpoint - 招银国际 maintains a "Buy" rating for 康方生物 (09926), citing positive overall survival (OS) trends from the HARMONi trial, which enhances confidence in its first-line indication potential [1] Group 1: Clinical Trial Results - Summit released the latest data from the HARMONi global clinical trial, evaluating the efficacy of AK112 combined with chemotherapy versus chemotherapy alone in second-line EGFR-TKI resistant NSCLC patients [2] - Chinese patients demonstrated superior progression-free survival (PFS) results, with a median PFS of 6.8 months for AK112 combined with chemotherapy compared to 4.4 months for chemotherapy alone (HR=0.52, p<0.001) [3] - In long-term follow-up, the PFS HR slightly worsened to 0.57, potentially due to increased data maturity in Western populations, with North American and European patients showing PFS HRs of 0.67 and 0.55 respectively [3] Group 2: Overall Survival Analysis - In the final OS analysis, the median OS for the AK112 combined chemotherapy group was 16.8 months compared to 14.0 months for the chemotherapy alone group, with an HR of 0.79 (95% CI: 0.62–1.01, p=0.0570) [4] - Long-term follow-up showed an improvement in OS HR to 0.78 (95% CI: 0.62–0.98) with a nominal p-value of 0.0332, indicating a positive trend despite the FDA's reliance on pre-specified analysis results [4] - North American patients exhibited strong OS results with an HR of 0.70, although the confidence interval was wide (0.38–1.30) [5]

Core Viewpoint - The report from CMB International maintains a "Buy" rating for Kangfang Biotech (09926), highlighting positive overall survival (OS) trends from the HARMONi trial, which enhances confidence in its first-line indication potential [1] Group 1: Clinical Trial Results - The HARMONi trial assessed the efficacy of AK112 combined with chemotherapy versus chemotherapy alone in second-line treatment for third-generation EGFR-TKI resistant NSCLC patients, showing that Western patients had inferior progression-free survival (PFS) risk ratios compared to Chinese patients [1] - In the primary PFS analysis (n=345, median follow-up of 22.3 months), the median PFS for AK112 combined with chemotherapy was 6.8 months compared to 4.4 months for chemotherapy alone (HR=0.52, p<0.001) [2] - In longer follow-up (median 29.7 months), the PFS HR slightly worsened to 0.57, attributed to increased data maturity in Western populations, with North American and European patients showing PFS HR of 0.67 and Chinese patients at 0.55 [2] Group 2: Overall Survival Analysis - In the final OS analysis (n=438, overall median follow-up of 29.7 months), the median OS for the AK112 combined group was 16.8 months versus 14.0 months for the chemotherapy group, with an HR of 0.79 (95% CI: 0.62–1.01, p=0.0570), indicating an overall positive OS trend [3] - In non-predefined longer follow-up (32.7 months), the OS HR improved to 0.78 (95% CI: 0.62–0.98) for the Western patient cohort, with a nominal p-value of 0.0332, emphasizing the importance of mature long-term OS data for evaluating efficacy in Western patients [3] - North American patients showed strong OS results with an HR of 0.70, despite a wide confidence interval (0.38–1.30), while European patients had limited sample size and follow-up time [4]

一款创新药要从中国走向全球市场，就必须叩开美国食品药品监督管理局（FDA）的大门。正因为这 样，AK112的海外研究进展和数据都格外受关注。 HARMONi是一项全球多中心、随机、双盲、安慰剂对照Ⅲ期研究，用于评估经三代EGFR-TKI治疗后 疾病进展的患者接受依沃西单抗联合化疗方案的疗效与安全性。该研究共随机入组438例患者（各组219 例），其中273例来自中国，165例（38%）来自北美和欧洲。中位年龄62岁，24.7%的患者在入组时存 在脑转移。 今年5月，Summit公布HARMONi的顶线结果，这是依沃西单抗的首个全球Ⅲ期临床数据披露。结果显 示，AK112在主要终点PFS上取得统计学显著且具有临床意义的改善，风险比（HR）为0.52；在另一主 要终点OS（总生存期）上则显示出积极趋势，但未达到统计学显著获益，风险比为0.79（p=0.057）。 OS被认为是FDA批准药物的主要指标之一，这一结果意味着AK112的上市预期延后，Summit和康方生 物股价重挫。 《每日经济新闻》记者注意到，此次Summit更新公布了HARMONi研究更长随访时间的临床研究数据， PFS和OS结果较今年5月公布的数 ...

Group 1 - Citic Lyon maintains "outperform" rating for Kangfang Biotech with a target price of HKD 177, citing excellent treatment performance from the global Phase III clinical study of Ivoris monoclonal antibody [1] - Goldman Sachs maintains "buy" rating for Meituan with a target price of HKD 144, expecting continued leadership in local services as the instant retail market expands [1] - Jianyin International maintains "outperform" rating for BYD, lowering the target price to HKD 115.7 due to a stock split, while highlighting the company's strong supply chain capabilities [1] Group 2 - Dongfang Caifu maintains "accumulate" rating for Pop Mart, noting strong performance in H1 2025 and potential for growth through IP exploration and global store expansion [2] - Goldman Sachs maintains "buy" rating for Ping An Insurance, raising the H-share target price to HKD 61, anticipating profit margin advantages from recent product repricing [3] - Goldman Sachs upgrades Luoyang Molybdenum to "buy" with a target price increase to HKD 10.8, driven by a 38% increase in regular profit due to rising copper and rare metal prices [4] Group 3 - Jefferies maintains "buy" rating for MicroPort with a target price increase to HKD 35, citing strong visibility in order growth and manageable competition in the domestic market [4] - Citic Securities maintains "buy" rating for Li Auto with a target price of HKD 151, expecting quarterly improvements in automotive business due to sales channel adjustments and new model launches [5] - CMB International upgrades UBTECH to "buy" with a target price increase to HKD 140, driven by strong orders for humanoid robots and rapid capacity expansion [6]

Core Viewpoint - CITIC Securities maintains a target price of HKD 177 for CanSino Biologics (09926) and a "outperform" rating following the positive trends observed in the global Phase III Harmoni study data for ivonescimab in treating second-line EGFR+ non-small cell lung cancer (NSCLC) [1] Group 1 - The Harmoni study data shows an improvement in overall survival (OS) risk trend from 0.79 to 0.78 [1] - The risk ratios reported for North America and Asia subgroups are 0.7 and 0.76, respectively, indicating strong performance [1] - The next key catalyst to watch is the results from the Phase III head-to-head clinical trial of Harmoni-6 versus tislelizumab, which will be presented at the 2025 European Society for Medical Oncology (ESMO) [1]

Core Viewpoint - Citic Securities maintains a target price of HKD 177 for Kangfang Biopharma (09926) and a "outperform" rating, following the positive trends observed in the global Phase III Harmoni study data for ivonescimab in treating second-line EGFR+ non-small cell lung cancer (NSCLC) [1] Group 1 - The Harmoni study showed an improvement in overall survival (OS) risk trend from 0.79 to 0.78, with risk ratios reported at 0.7 for North America and 0.76 for Asia, indicating strong performance [1] - The next anticipated catalyst is the presentation of results from the Harmoni-6 head-to-head Phase III trial against tislelizumab at the 2025 European Society for Medical Oncology (ESMO) [1]